mAbs not effective vs SA or Brazil strains27 Jan 2021 11:03
https://twitter.com/PeterHorby/status/1354322760726683649
Science Paper here = https://t.co/AlV2gI2WAO?amp=1
Important new data released I suggest everybody read and the implications for mAbs treatments if Brazil or South Africa (or any E484K) mutation becomes prevelent.
Our findings have relevance to the use of mAb to treat or prevent SARS-CoV-2. Both UK?8 and SA?9 are resistant to neutralization by mAbs directed to the NTD supersite (Figs. 2c, 2d, & Extended Data Fig. 3b). More importantly, SA?9 is resistant to a major group of potent mAbs that target the RBM, including two authorized for emergency use (Fig. 2c). LY-CoV555 is inactive against SA?9, and the activity of REGN10933 is impaired (Fig. 2b) while its combination with REGN10987 remains potent (Fig. 2e). Several other mAbs in development are similarly impaired (Figs. 2c, 2e, & Extended Data Fig. 4b) against this variant. Decisions on the use of these mAbs will depend heavily on the local prevalence of B.1.351 or B.1.1.28, thus highlighting the importance of viral genomic surveillance worldwide and proactive development of next-generation antibody therapeutics, including combinations that target antigenically distinct epitopes.